文献速递认知障碍与痴呆

用淀粉样蛋白PET对β-淀粉样蛋白病理进行分期

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography.
PubMed 文献 · JAMA Neurol · 2019-01-01

这项纵向多中心队列研究利用741名参与者的18F-florbetapir PET数据,构建了0至3期的β-淀粉样蛋白(Aβ)体内分期系统,并验证其纵向有效性。研究发现不同分期对应不同的Aβ累积脑区,且更高分期与脑脊液Aβ42降低、tau升高、认知下降和萎缩加速相关,结果在独立队列中得以重复。

要点

  • Aβ PET分期系统能有效追踪阿尔茨海默病病理进展。
  • 早期Aβ累积区域包括楔前叶、后扣带回和眶额皮质等。
  • 更高分期与脑脊液生物标志物异常及认知、萎缩加速相关。

核心结论

  • 该稳健的Aβ累积分期系统可能有助于监测阿尔茨海默病全程。
  • 分期进展可能取决于不同脑区的选择性易损性。

研究设计与样本

  • 纵向多中心队列研究,使用阿尔茨海默病神经影像学倡议数据库2010年6月9日至2018年7月12日的扫描数据。
  • 共纳入741人:304名无认知障碍、384名轻度认知障碍、53名阿尔茨海默病痴呆。
  • 利用脑脊液Aβ42和18F-florbetapir PET数据确定Aβ累积的早期、中期和晚期区域,构建0至3期分期。
  • 在2、4、6年进行随访,并使用独立队列(瑞典BioFINDER)和艾伦人脑图谱基因表达信息进行重复和验证。

主要发现

  • 在741名参与者的2072次PET扫描中,2039次(98.4%)被明确分期。
  • 基线时,0期(n=402)进展至更高分期的概率为14.7%(95%CI,11.2%-18.1%);1期(n=21)为71.4%(95%CI,50.0%-90.9%);2期(n=79)为53.1%(95%CI,42.2%-64.0%)。
  • 741名参与者中有7人(0.9%)退回至较低分期。
  • 更高分期与更低的脑脊液Aβ42浓度(从基线1期起)、更高的脑脊液P-tau(从1期起)和T-tau(从2期起)、加速的认知下降(从2期起)和萎缩(从3期起)相关,即使调整临床诊断后仍显著。
  • 关键发现在BioFINDER队列(N=474)中得到重复。

关键数值与推荐

  • 早期Aβ累积区域包括楔前叶、后扣带回、峡部扣带回、岛叶以及内侧和外侧眶额皮质。
  • 晚期区域包括舌回、距状沟周围皮质、中央旁皮质、中央前回和中央后回皮质。
  • 中期区域包括其余累积速率增加的脑区。
  • 不同分期的脑区基因表达谱存在差异,尤其涉及电压门控离子通道活动相关基因,还涉及血液循环、轴突导向和脂质转运。

临床怎么用

  • 该分期系统可用于监测阿尔茨海默病患者的Aβ病理进展。
  • 分期与脑脊液tau标志物、认知和萎缩的关联有助于解读PET结果。

局限性

  • 原始摘要未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Different brain regions appear to be involved during β-amyloid (Aβ) accumulation in Alzheimer disease (AD), but a longitudinally valid system to track Aβ stages in vivo using positron emission tomography (PET) is lacking. OBJECTIVE: To construct a longitudinally valid in vivo staging system for AD using amyloid PET. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal multicenter cohort study using data accessed on August 20, 2018, from the Alzheimer's Disease Neuroimaging Initiative database of scans performed from June 9, 2010, to July 12, 2018, from 741 persons: 304 without cognitive impairment, 384 with mild cognitive impairment, and 53 with AD dementia. Cerebrospinal fluid (CSF) Aβ42 and fluorine 18-labeled florbetapir (18F-florbetapir) data were used to determine early, intermediate, and late regions of Aβ accumulation. β-Amyloid stages ranging from 0 to 3 were constructed using these composites. Each subsequent stage required involvement of more advanced regions. Patients were followed up at 2, 4, and 6 years. Replication and validation were conducted using an independent cohort (Swedish BioFINDER) and gene expression information from the Allen Human Brain Atlas database. Analyses were conducted August 21, 2018, to May 24, 2019. MAIN OUTCOMES AND MEASURES: The main outcome was change in stage. Stages were compared for diagnosis, CSF biomarkers of tau, and longitudinal atrophy, cognitive measures, and regional gene expression. Transitions between stages were tested using longitudinal 18F-florbetapir data. RESULTS: Among 641 participants with CSF Aβ42 data and at least two 18F-florbetapir scans, 335 (52.3%) were male. The early region of Aβ accumulation included the precuneus, posterior cingulate, isthmus cingulate, insula, and medial and lateral orbitofrontal cortices. The late region included the lingual, pericalcarine, paracentral, precentral, and postcentral cortices. The intermediate region included remaining brain regions with increased accumulation rates. In 2072 PET scans from 741 participants, 2039 (98.4%) were unambiguously staged. At baseline, participants with stage 0 (n = 402) had a 14.7% (95% CI, 11.2%-18.1%) probability of progression to a higher stage; stage 1 (n = 21), 71.4% (95% CI, 50.0%-90.9%); and stage 2 (n = 79), 53.1% (95% CI, 42.2%-64.0%). Seven of the 741 participants (0.9%) reverted to a lower stage. Higher stages were associated with lower CSF Aβ42 concentrations (from stage 1 at baseline), greater CSF P-tau (from stage 1) and CSF T-tau (from stage 2), and accelerated cognitive decline (from stage 2) and atrophy (from stage 3), even when adjusting for clinical diagnosis. Key findings were replicated in the BioFINDER cohort (N = 474). The regions of different stages differed by gene expression profiles when using the transcriptome from the Allen Human Brain Atlas, especially involving genes associated with voltage-gated ion channel activity especially involving genes associated with voltage-gated ion channel activity, but also blood circulation, axon guidance, and lipid transportation. CONCLUSIONS AND RELEVANCE: Results of this study suggest that this robust staging system of Aβ accumulation may be useful for monitoring patients throughout the course of AD. Progression through stages may depend on underlying selective vulnerability in different brain regions.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Mattsson N, Palmqvist S, Stomrud E, et al. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurol. 2019. PMID: 31314895. doi:10.1001/jamaneurol.2019.2214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。